HYPR, US44916K1060

Hyperfine stock in focus after record Q3 revenue and tighter margins

Published on 11/19/2026 at 03:07 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Hyperfine stock stays in focus after record third-quarter revenue and gross profit. Management kept its revenue and cash-burn outlook for 2026.

Growth Meets a Narrower Loss

  • Hyperfine sold 14 Swoop systems in the third quarter, up from eight a year earlier.
  • Net cash burn fell to USD 5.6 million, while revenue exceeded quarterly cash burn for the first time.
  • Management expects a year-end 2026 filing for a new Swoop contrast-imaging application with the FDA.
HYPR, US44916K1060, Illustration mit AI erstellt.

Hyperfine reported record third-quarter revenue and gross profit on November 9, 2026, while narrowing its operating loss and reducing cash burn. In its investor release, the medical-imaging company said revenue reached USD 6.0 million, up 73 percent from the year-earlier quarter and 53 percent from the second quarter.

Revenue Growth Improves Operating Leverage

Hyperfine sold 14 commercial Swoop systems during the quarter, compared with eight a year earlier. Gross profit rose to USD 3.4 million from USD 1.8 million, lifting gross margin to 57 percent from 54 percent.

The operating loss narrowed to USD 7.3 million from USD 8.9 million. Net loss was USD 6.0 million, or USD 0.06 per share, compared with USD 11.0 million, or USD 0.14 per share, in the prior-year quarter. The latest result included a USD 1.5 million gain from a change in the fair value of warrant liabilities, while the prior-year period included a USD 2.3 million loss.

Cash Burn Falls Below Quarterly Revenue

Net cash burn declined to USD 5.6 million from USD 7.9 million in the second quarter and USD 5.9 million a year earlier. Quarterly revenue exceeded net cash burn for the first time, while cash and cash equivalents stood at USD 37.9 million on September 30, 2026.

Management maintained its 2026 revenue outlook of approximately USD 20 million to USD 22 million and its net cash-burn outlook of approximately USD 26 million to USD 28 million. The company narrowed its full-year gross-margin range to 52.5 percent to 55 percent by raising the lower end from 50 percent.

Regulatory and International Expansion

Hyperfine completed enrollment in its Contrast PMR study and said an FDA submission remains on track for the end of 2026. The company also launched the Swoop Model 2 in Europe and the United Kingdom, with sales in four international markets, and signed an exclusive distribution agreement covering Kuwait and the United Arab Emirates.

Portable Brain Imaging Focus

Hyperfine develops portable, ultra-low-field magnetic resonance imaging systems for brain imaging at multiple points of professional care. Its Swoop system is designed for settings where a conventional MRI examination is not clinically practical, and the company operates from the United States. The business is more specialized and portable than conventional hospital-based MRI providers, with its commercial focus centered on accessible brain imaging.

Hyperfine company facts

  • Company: Hyperfine, Inc.
  • ISIN: US44916K1060
  • Ticker: HYPR
  • Listing: Nasdaq
  • Third-quarter revenue: USD 6.0 million for the quarter ended September 30, 2026
  • Third-quarter operating loss: USD 7.3 million
  • Cash and cash equivalents: USD 37.9 million as of September 30, 2026
  • 2026 revenue outlook: Approximately USD 20 million to USD 22 million

The broader U.S. market backdrop is covered in the S&P 500 market reports.

More news and analyses on Hyperfine stock are available here.

Disclaimer...
en | US44916K1060 | HYPR | boerse | 70533350 | bgmi